# A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

> **NCT05514509** · PHASE4 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 370 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** APRETUDE
- **DRUG:** Cabotegravir tablet

## Key facts

- **NCT ID:** NCT05514509
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-28
- **Primary completion:** 2025-09-02
- **Final completion:** 2025-09-02
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514509, "A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05514509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*